Onconetix (NASDAQ:ONCO) Shares to Reverse Split on Friday, November 6th

Onconetix, Inc. (NASDAQ:ONCO) shares are going to reverse split on the morning of Friday, November 6th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 5th.

Onconetix Stock Performance

Shares of NASDAQ ONCO opened at $0.56 on Monday. The company has a market cap of $330,429.00, a PE ratio of 0.00 and a beta of 2.61. Onconetix has a fifty-two week low of $0.34 and a fifty-two week high of $186.50. The business has a 50-day simple moving average of $0.66 and a two-hundred day simple moving average of $14.99.

Onconetix (NASDAQ:ONCO) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4,505.00) by $4,503.72. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ONCO. Wall Street Zen raised Onconetix from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings raised shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Onconetix Company Profile

Onconetix, Inc is a biotechnology company focused on developing and commercializing diagnostic and therapeutic products for men’s health. The company’s portfolio is centered primarily on prostate health, with products intended to support the detection, risk assessment and treatment of prostate-related conditions.

Its lead diagnostic product is Proclarix, a blood-based test designed to help assess the risk of clinically significant prostate cancer in men with elevated prostate-specific antigen (PSA) levels.